Metabolic therapy for heart failure including diastolic heart failure

Nishat Siddiqi, Dana Dawson, Amelia Rudd, Michael Frenneaux*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Cardiac energetic impairment is a feature of systolic heart failure irrespective of the underlying etiology, and the magnitude of this impairment is predictive of subsequent mortality. It is also a feature of other forms of heart muscle diseases including hypertrophic cardiomyopathy and heart failure with normal ejection fraction. While the adult heart normally uses predominantly free fatty acids to generate energy, this consumes more oxygen than the use of carbohydrate to generate energy. In the context of heart muscle disease the reduction in efficiency of fatty acid versus carbohydrate utilization may be substantial. This provides the rationale for the use of drugs that inhibit fatty acid utilization and increase carbohydrate utilization. These agents either prevent the uptake of long chain fatty acids into the mitochondria (eg, perhexiline) or inhibit fatty acid β-oxidation (eg, trimetazidine). Studies in patients with systolic heart failure have shown encouraging results with increased cardiac performance and exercise capacity.

Original languageEnglish
Pages (from-to)18-24
Number of pages7
JournalHeart and Metabolism
Issue number57
Publication statusPublished - 1 Dec 2012

Fingerprint

Diastolic Heart Failure
Fatty Acids
Heart Failure
Systolic Heart Failure
Carbohydrates
Heart Diseases
Myocardium
Perhexiline
Trimetazidine
Hypertrophic Cardiomyopathy
Therapeutics
Nonesterified Fatty Acids
Mitochondria
Exercise
Oxygen
Mortality
Pharmaceutical Preparations

Keywords

  • Cardiac energetics
  • Cardiac metabolism
  • Cardiomyopathy
  • Heart failure
  • Metabolic therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Metabolic therapy for heart failure including diastolic heart failure. / Siddiqi, Nishat; Dawson, Dana; Rudd, Amelia; Frenneaux, Michael.

In: Heart and Metabolism, No. 57, 01.12.2012, p. 18-24.

Research output: Contribution to journalArticle

Siddiqi, Nishat ; Dawson, Dana ; Rudd, Amelia ; Frenneaux, Michael. / Metabolic therapy for heart failure including diastolic heart failure. In: Heart and Metabolism. 2012 ; No. 57. pp. 18-24.
@article{8e6fa98f2fc74cb58931d83a8020cfe6,
title = "Metabolic therapy for heart failure including diastolic heart failure",
abstract = "Cardiac energetic impairment is a feature of systolic heart failure irrespective of the underlying etiology, and the magnitude of this impairment is predictive of subsequent mortality. It is also a feature of other forms of heart muscle diseases including hypertrophic cardiomyopathy and heart failure with normal ejection fraction. While the adult heart normally uses predominantly free fatty acids to generate energy, this consumes more oxygen than the use of carbohydrate to generate energy. In the context of heart muscle disease the reduction in efficiency of fatty acid versus carbohydrate utilization may be substantial. This provides the rationale for the use of drugs that inhibit fatty acid utilization and increase carbohydrate utilization. These agents either prevent the uptake of long chain fatty acids into the mitochondria (eg, perhexiline) or inhibit fatty acid β-oxidation (eg, trimetazidine). Studies in patients with systolic heart failure have shown encouraging results with increased cardiac performance and exercise capacity.",
keywords = "Cardiac energetics, Cardiac metabolism, Cardiomyopathy, Heart failure, Metabolic therapy",
author = "Nishat Siddiqi and Dana Dawson and Amelia Rudd and Michael Frenneaux",
note = "Acknowledgements Professor Frenneaux is the inventor of method of use patents for perhexiline in heart muscle diseases.",
year = "2012",
month = "12",
day = "1",
language = "English",
pages = "18--24",
journal = "Heart and Metabolism",
issn = "1566-0338",
publisher = "Les Laboratoires Servier",
number = "57",

}

TY - JOUR

T1 - Metabolic therapy for heart failure including diastolic heart failure

AU - Siddiqi, Nishat

AU - Dawson, Dana

AU - Rudd, Amelia

AU - Frenneaux, Michael

N1 - Acknowledgements Professor Frenneaux is the inventor of method of use patents for perhexiline in heart muscle diseases.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Cardiac energetic impairment is a feature of systolic heart failure irrespective of the underlying etiology, and the magnitude of this impairment is predictive of subsequent mortality. It is also a feature of other forms of heart muscle diseases including hypertrophic cardiomyopathy and heart failure with normal ejection fraction. While the adult heart normally uses predominantly free fatty acids to generate energy, this consumes more oxygen than the use of carbohydrate to generate energy. In the context of heart muscle disease the reduction in efficiency of fatty acid versus carbohydrate utilization may be substantial. This provides the rationale for the use of drugs that inhibit fatty acid utilization and increase carbohydrate utilization. These agents either prevent the uptake of long chain fatty acids into the mitochondria (eg, perhexiline) or inhibit fatty acid β-oxidation (eg, trimetazidine). Studies in patients with systolic heart failure have shown encouraging results with increased cardiac performance and exercise capacity.

AB - Cardiac energetic impairment is a feature of systolic heart failure irrespective of the underlying etiology, and the magnitude of this impairment is predictive of subsequent mortality. It is also a feature of other forms of heart muscle diseases including hypertrophic cardiomyopathy and heart failure with normal ejection fraction. While the adult heart normally uses predominantly free fatty acids to generate energy, this consumes more oxygen than the use of carbohydrate to generate energy. In the context of heart muscle disease the reduction in efficiency of fatty acid versus carbohydrate utilization may be substantial. This provides the rationale for the use of drugs that inhibit fatty acid utilization and increase carbohydrate utilization. These agents either prevent the uptake of long chain fatty acids into the mitochondria (eg, perhexiline) or inhibit fatty acid β-oxidation (eg, trimetazidine). Studies in patients with systolic heart failure have shown encouraging results with increased cardiac performance and exercise capacity.

KW - Cardiac energetics

KW - Cardiac metabolism

KW - Cardiomyopathy

KW - Heart failure

KW - Metabolic therapy

UR - http://www.scopus.com/inward/record.url?scp=84874474278&partnerID=8YFLogxK

M3 - Article

SP - 18

EP - 24

JO - Heart and Metabolism

JF - Heart and Metabolism

SN - 1566-0338

IS - 57

ER -